FLUDARABINE PHARMACOKINETICS IN NONMYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTAT

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究项目的总体目标是研究氟达拉滨在接受非清髓性造血细胞移植（HCT）患者中的药代动力学。目的研究氟达拉滨在HCT患者初给药和稳态时的药代动力学特征。目的II和III将研究药代动力学测量及其与肾功能、植入和神经毒性的关系。目的四是获取患者DNA进行药代动力学研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall objective of this research project is to investigate the pharmacokinetics of fludarabine in patients undergoing nonmyeloablative hematopoietic cell transplantation (HCT). Aim I will characterize pharmacokinetics of fludarabine in HCT patients at first dose and steady state. Aims II and III will investigate pharmacokinetic measures and their relationship to renal function, engraftment and neurotoxicity. Aim IV is to obtain patient DNA for pharmacokinetic studies.